Gilead Sciences annual gross margin
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gilead Sciences Gross Margin Growth & History (GILD)
Gilead Sciences's gross margin was 78.83% for fiscal 2025.
View full Gilead Sciences company overviewGilead Sciences annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 78.83% | +0.57 pp |
| 2024 | 2024-12-31 | 78.26% | +2.22 pp |
| 2023 | 2023-12-31 | 76.04% | −3.23 pp |
| 2022 | 2022-12-31 | 79.26% | +3.44 pp |
| 2021 | 2021-12-31 | 75.82% | −5.66 pp |
| 2020 | 2020-12-31 | 81.48% | +2.31 pp |
| 2019 | 2019-12-31 | 79.18% | +1.11 pp |
| 2018 | 2018-12-31 | 78.07% | −5.19 pp |
| 2017 | 2017-12-31 | 83.26% | −2.72 pp |
| 2016 | 2016-12-31 | 85.98% | −1.75 pp |
| 2015 | 2015-12-31 | 87.73% | +2.95 pp |
| 2014 | 2014-12-31 | 84.78% | +10.30 pp |
| 2013 | 2013-12-31 | 74.48% | −0.05 pp |
| 2012 | 2012-12-31 | 74.53% | −0.13 pp |
| 2011 | 2011-12-31 | 74.67% | −1.81 pp |
| 2010 | 2010-12-31 | 76.48% | −0.77 pp |
| 2009 | 2009-12-31 | 77.24% | −1.63 pp |
| 2008 | 2008-12-31 | 78.87% | −2.95 pp |
| 2007 | 2007-12-31 | 81.83% | — |
Gilead Sciences quarterly gross margin
Q2.08
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 79.76% | +0.96 pp |
| Q1 2026 | 2026-03-31 | 79.24% | +2.34 pp |
| Q4 2025 | 2025-12-31 | 79.51% | +0.40 pp |
| Q3 2025 | 2025-09-30 | 79.80% | +0.67 pp |
| Q2 2025 | 2025-06-30 | 78.81% | +1.01 pp |
| Q1 2025 | 2025-03-31 | 76.90% | +0.11 pp |
| Q4 2024 | 2024-12-31 | 79.11% | +8.49 pp |
| Q3 2024 | 2024-09-30 | 79.14% | +1.33 pp |
| Q2 2024 | 2024-06-30 | 77.80% | −0.35 pp |
| Q1 2024 | 2024-03-31 | 76.79% | −1.16 pp |
| Q4 2023 | 2023-12-31 | 70.62% | −10.49 pp |
| Q3 2023 | 2023-09-30 | 77.80% | −2.39 pp |
| Q2 2023 | 2023-06-30 | 78.15% | +1.18 pp |
| Q1 2023 | 2023-03-31 | 77.94% | −0.45 pp |
| Q4 2022 | 2022-12-31 | 81.11% | +17.37 pp |
| Q3 2022 | 2022-09-30 | 80.19% | −3.33 pp |
| Q2 2022 | 2022-06-30 | 76.96% | −0.68 pp |
| Q1 2022 | 2022-03-31 | 78.39% | −0.42 pp |
| Q4 2021 | 2021-12-31 | 63.74% | −16.17 pp |
| Q3 2021 | 2021-09-30 | 83.52% | +2.15 pp |
| Q2 2021 | 2021-06-30 | 77.64% | −0.19 pp |
| Q1 2021 | 2021-03-31 | 78.81% | −2.26 pp |
| Q4 2020 | 2020-12-31 | 79.91% | +9.95 pp |
| Q3 2020 | 2020-09-30 | 81.37% | +1.41 pp |
| Q2 2020 | 2020-06-30 | 77.83% | −3.20 pp |
| Q1 2020 | 2020-03-31 | 81.07% | +0.73 pp |
| Q4 2019 | 2019-12-31 | 69.96% | −0.98 pp |
| Q3 2019 | 2019-09-30 | 79.96% | +1.89 pp |
| Q2 2019 | 2019-06-30 | 81.04% | +4.13 pp |
| Q1 2019 | 2019-03-31 | 80.34% | +1.73 pp |
| Q4 2018 | 2018-12-31 | 70.94% | −6.06 pp |
| Q3 2018 | 2018-09-30 | 78.07% | −4.39 pp |
| Q2 2018 | 2018-06-30 | 76.91% | −5.99 pp |
| Q1 2018 | 2018-03-31 | 78.62% | −4.70 pp |
| Q4 2017 | 2017-12-31 | 77.00% | −6.89 pp |
| Q3 2017 | 2017-09-30 | 82.46% | −1.22 pp |
| Q2 2017 | 2017-06-30 | 82.90% | −4.38 pp |
| Q1 2017 | 2017-03-31 | 83.32% | +0.08 pp |
| Q4 2016 | 2016-12-31 | 83.89% | −2.48 pp |
| Q3 2016 | 2016-09-30 | 83.68% | −2.48 pp |
| Q2 2016 | 2016-06-30 | 87.28% | +0.82 pp |
| Q1 2016 | 2016-03-31 | 83.24% | −2.65 pp |
| Q4 2015 | 2015-12-31 | 86.37% | +2.17 pp |
| Q3 2015 | 2015-09-30 | 86.16% | +3.72 pp |
| Q2 2015 | 2015-06-30 | 86.46% | +2.48 pp |
| Q1 2015 | 2015-03-31 | 85.90% | +4.72 pp |
| Q4 2014 | 2014-12-31 | 84.21% | +14.18 pp |
| Q3 2014 | 2014-09-30 | 82.44% | +9.57 pp |
| Q2 2014 | 2014-06-30 | 83.98% | +12.68 pp |
| Q1 2014 | 2014-03-31 | 81.18% | +11.70 pp |
| Q4 2013 | 2013-12-31 | 70.03% | −0.86 pp |
| Q3 2013 | 2013-09-30 | 72.87% | +0.31 pp |
| Q2 2013 | 2013-06-30 | 71.29% | +0.45 pp |
| Q1 2013 | 2013-03-31 | 69.48% | −1.82 pp |
| Q4 2012 | 2012-12-31 | 70.90% | +0.50 pp |
| Q3 2012 | 2012-09-30 | 72.56% | +0.26 pp |
| Q2 2012 | 2012-06-30 | 70.84% | +0.39 pp |
| Q1 2012 | 2012-03-31 | 71.30% | −0.84 pp |
| Q4 2011 | 2011-12-31 | 70.39% | −1.35 pp |
| Q3 2011 | 2011-09-30 | 72.30% | +0.66 pp |
| Q2 2011 | 2011-06-30 | 70.45% | +0.37 pp |
| Q1 2011 | 2011-03-31 | 72.14% | +7.53 pp |
| Q4 2010 | 2010-12-31 | 71.74% | +6.25 pp |
| Q3 2010 | 2010-09-30 | 71.63% | +2.84 pp |
| Q2 2010 | 2010-06-30 | 70.08% | −1.89 pp |
| Q1 2010 | 2010-03-31 | 64.61% | −8.45 pp |
| Q4 2009 | 2009-12-31 | 65.49% | — |
| Q3 2009 | 2009-09-30 | 68.79% | −9.31 pp |
| Q2 2009 | 2009-06-30 | 71.96% | −7.25 pp |
| Q1 2009 | 2009-03-31 | 73.06% | — |
| Q3 2008 | 2008-09-30 | 78.11% | — |
| Q2 2008 | 2008-06-30 | 79.21% | — |
Gilead Sciences gross margin trends
Over the last five fiscal years, Gilead Sciences's gross margin decreased from 81.48% to 78.83%, a change of −2.65 percentage points. The latest reported quarter, Q2 2026, shows 79.76%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gilead Sciences source filings ↗Community posts
Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and ...
Gilead agrees $1.275 billion purchase of PepStar's oral inflammation program
Gilead ($GILD) agreed to acquire worldwide rights to PepStar's investigational oral IL-23 receptor inhibitor program, led by HCXT-2001. The agreement calls for $1.275 billion in upfront cash consideration payable at closing, subject to cust ...
